Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
81.77
-0.06 (-0.07%)
At close: Dec 5, 2025, 4:00 PM EST
81.76
-0.01 (-0.01%)
After-hours: Dec 5, 2025, 6:05 PM EST
Tarsus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 366.1 | 182.95 | 17.45 | 25.82 | 57.03 | - | Upgrade
|
| Revenue Growth (YoY) | 182.44% | 948.62% | -32.42% | -54.73% | - | - | Upgrade
|
| Cost of Revenue | 87.84 | 66.21 | 51.91 | 43.58 | 43.79 | 18.83 | Upgrade
|
| Gross Profit | 278.26 | 116.74 | -34.46 | -17.76 | 13.24 | -18.83 | Upgrade
|
| Selling, General & Admin | 365.67 | 237.31 | 108.7 | 44.95 | 25.4 | 8.17 | Upgrade
|
| Operating Expenses | 365.67 | 237.31 | 108.7 | 44.95 | 25.4 | 8.17 | Upgrade
|
| Operating Income | -87.41 | -120.57 | -143.16 | -62.71 | -12.16 | -27 | Upgrade
|
| Interest Expense | -9.03 | -7.85 | -3.35 | -2.2 | - | - | Upgrade
|
| Interest & Investment Income | 15.44 | 15.01 | 10.34 | 3.5 | 0.04 | 0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.19 | 0.59 | -0.1 | 0.09 | -0 | - | Upgrade
|
| EBT Excluding Unusual Items | -82.19 | -112.82 | -136.27 | -61.33 | -12.12 | -26.81 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.03 | -0.79 | 0.38 | -0.77 | -1.58 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.07 | - | Upgrade
|
| Other Unusual Items | - | -1.94 | - | - | - | - | Upgrade
|
| Pretax Income | -81.16 | -115.55 | -135.89 | -62.1 | -13.77 | -26.81 | Upgrade
|
| Income Tax Expense | - | - | - | -0 | 0.06 | 0 | Upgrade
|
| Net Income | -81.16 | -115.55 | -135.89 | -62.09 | -13.83 | -26.81 | Upgrade
|
| Net Income to Common | -81.16 | -115.55 | -135.89 | -62.09 | -13.83 | -26.81 | Upgrade
|
| Shares Outstanding (Basic) | 41 | 38 | 29 | 25 | 21 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 41 | 38 | 29 | 25 | 21 | 6 | Upgrade
|
| Shares Change (YoY) | 12.21% | 27.98% | 19.35% | 19.78% | 231.12% | 162.72% | Upgrade
|
| EPS (Basic) | -1.99 | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 | Upgrade
|
| EPS (Diluted) | -1.99 | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 | Upgrade
|
| Free Cash Flow | -57.54 | -84.59 | -119 | -49.54 | 3.16 | -21.59 | Upgrade
|
| Free Cash Flow Per Share | -1.41 | -2.25 | -4.05 | -2.01 | 0.15 | -3.48 | Upgrade
|
| Gross Margin | 76.01% | 63.81% | -197.50% | -68.81% | 23.22% | - | Upgrade
|
| Operating Margin | -23.88% | -65.90% | -820.53% | -242.92% | -21.32% | - | Upgrade
|
| Profit Margin | -22.17% | -63.16% | -778.89% | -240.51% | -24.25% | - | Upgrade
|
| Free Cash Flow Margin | -15.72% | -46.24% | -682.04% | -191.88% | 5.54% | - | Upgrade
|
| EBITDA | -85.61 | -119.34 | -142.28 | -62.39 | -11.85 | -26.9 | Upgrade
|
| EBITDA Margin | -23.38% | -65.23% | - | -241.66% | -20.77% | - | Upgrade
|
| D&A For EBITDA | 1.81 | 1.23 | 0.88 | 0.33 | 0.31 | 0.1 | Upgrade
|
| EBIT | -87.41 | -120.57 | -143.16 | -62.71 | -12.16 | -27 | Upgrade
|
| EBIT Margin | -23.88% | -65.90% | - | -242.92% | -21.32% | - | Upgrade
|
| Revenue as Reported | 366.1 | 182.95 | 17.45 | 25.82 | 57.03 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.